MedTrace Logo

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

NCT00280917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2023-09-18

Study results available
· View outcomes & findings →

Summary

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

Conditions

Interventions

DRUG

CF101

Sponsors & Collaborators

  • Can-Fite BioPharma

    lead INDUSTRY

Principal Investigators

  • Michael H Silverman, MD · BioStrategics Consulting Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States
  • Bulgaria
  • Israel
  • Poland
  • Romania
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280917 on ClinicalTrials.gov